يعرض 1 - 9 نتائج من 9 نتيجة بحث عن '"Angell, HK"', وقت الاستعلام: 0.42s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
    Academic Journal

    المصدر: Lancet (London, England). 391(10135):2128-2139

  3. 3
    Academic Journal
  4. 4
    Academic Journal
  5. 5
    Conference

    المساهمون: Basser Center, University of Pennsylvania, Private Practice - Domchek, Philadelphia

    Relation: https://dx.doi.org/10.1093/annonc/mdz253.017; Domchek S, Postel-Vinay S, Im SA, Park YH, Delord JP, Italiano A, et al. 1191O Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC). Annals of Oncology. 2019;30(Supplement_5):477.; http://hdl.handle.net/10541/622590; Annals of Oncology

  6. 6
    Conference

    المساهمون: Basser Center for BRCA University of Pennsylvania, Philadelphia

    Relation: https://dx.doi.org/10.1158/1538-7445.SABCS18-PD5-04; Domchek SM, Postel-Vinay S, Im SA, Hee Park Y, Delord JP, Italiano A, et al. Abstract PD5-04: an open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): updated results in patients with germlineBRCA-mutated (gBRCAm) metastatic breast cancer (MBC). Cancer Res. 2019;79(4):PD5-04-PD5-.; http://hdl.handle.net/10541/622145; Cancer Research

  7. 7
    Conference

    المساهمون: Basser Center for BRCA University of Pennsylvania, Philadelphia

    Relation: https://dx.doi.org/10.1158/1538-7445.SABCS18-OT3-05-03; Domchek SM, Postel-Vinay S, Im SA, Hee Park Y, Delord JP, Italiano A, et al. Abstract OT3-05-03: MEDIOLA: an open-label, phase I/II basket study of olaparib (PARP inhibitor) and durvalumab (anti-PD-L1 antibody) – Additional breast cancer cohorts. Cancer Res. 2019;79(4):OT3-05-3-OT3--3.; http://hdl.handle.net/10541/622146; Cancer Research

  8. 8
    Academic Journal

    المصدر: Thress , KS , Jacobs , V , Angell , HK , Chih-Hsin Yang , J , Sequist , LV , Blackhall , F , Su , WC , Schuler , M , Wolf , J , Gold , KA , Cantarini , M , Barrett , JC & Janne , PA 2017 , ' BRIEF REPORT: Modulation of biomarker expression by osimertinib: Results of the paired tumor biopsy cohorts of the AURA Phase I trial ' , Journal of Thoracic Oncology , vol. 12 , no. 10 , pp. 1588-1594 . https://doi.org/10.1016/j.jtho.2017.07.011

  9. 9
    Academic Journal

    المساهمون: Galon, J, Franck, P, Marincola, Fm, Angell, Hk, Thurin, M, Lugli, A, Zlobec, I, Berger, A, Bifulco, C, Botti, G, Tatangelo, F, Britten, Cm, Kreiter, S, Chouchane, L, Delrio, P, Hartmann, A, Asslaber, M, Maio, M, Masucci, Gv, Mihm, M, Vidal-Vanaclocha, F, Allison, Jp, Gnjatic, S, Hakansson, L, Huber, C, Singh-Jasuja, H, Ottensmeier, C, Zwierzina, H, Laghi, L, Grizzi, F, Ohashi, P, Shaw, Pa, Clarke, Ba, Wouters, Bg, Kawakami, Y, Hazama, S, Okuno, K, Wang, E, O'Donnell-Tormey, J, Lagorce, C, Pawelec, G, Nishimura, Mi, Hawkins, R, Lapointe, R, Lundqvist, A, Khleif, Sn, Ogino, S, Gibbs, P, Waring, P, Sato, N, Torigoe, T, Itoh, K, Patel, P, Shukla, Sn, Palmqvist, R, Nagtegaal, Id, Wang, Y, D'Arrigo, C, Kopetz, S, Sinicrope, Fa, Trinchieri, G, Gajewski, Tf, Ascierto, Pa, Fox, Ba

    Relation: info:eu-repo/semantics/altIdentifier/wos/WOS:000315104900001; volume:10; firstpage:205; journal:JOURNAL OF TRANSLATIONAL MEDICINE; http://hdl.handle.net/11365/1081508; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84866852663